SPMS

News

Novartis’ Mayzent has been approved in Europe for adults with secondary progressive multiple sclerosis (SPMS) and active disease.

News

ADC Therapeutics' chances of upgrading its accelerated approval for DLBCL therapy Zynlonta to a full approval have taken a knock.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.